New Immune-Boosting drug GEN1042 tested in japanese cancer patients

NCT ID NCT06057038

Ongoing Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEN1042 (a biologic drug that targets CD40 and 4-1BB to boost immune response against cancer)
What this could lead to: If successful, this could lead to a new treatment option for Japanese patients with advanced solid tumors, potentially improving tumor control.
What could go wrong: This is an early Phase 1 trial with only 42 participants, focused on safety and dosing. It is too small and early to know if the drug will work or be safe for broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMOR

Contacts and locations

Show contact details

Locations

National Cancer Center East

Kashiwa, Japan
National Cancer Center Hospital

Tokyo, Japan
Tokyo Medical University Hospital

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.